Researchers at Cambridge and Meta developed a new method to measure human visual resolution, revealing that the human eye can perceive higher resolutions than previously thought in grayscale, but less so in color, which has implications for display technology and consumer choices.
Scientists have developed a retinal implant that significantly improves vision in people with advanced dry age-related macular degeneration, restoring the ability to read and recognize faces, with promising results from a clinical trial involving 38 patients.
EyePoint Pharmaceuticals has announced positive topline results from its Phase 2 DAVIO 2 trial of EYP-1901, a potential treatment for wet age-related macular degeneration (wet AMD). The trial met its primary endpoint, demonstrating statistical non-inferiority in change in best corrected visual acuity (BCVA) compared to the control group. The treatment also achieved key secondary endpoints, including a reduction in treatment burden and strong anatomical control. The results support the initiation of Phase 3 trials for EYP-1901, which could potentially lead to a paradigm shift in the treatment of wet AMD.